Estrella Immunopharma, Inc. (ESLAW) stock
ESLAWNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as ESLA
Số liệu tài chính tới Q1 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$0.06−0.00 (-2.08%)
Close on Nov 18, 2026Market cap $14.48MP/E –Yield –
Estrella Immunopharma r&d expenses
Research and development expenses are spending on new products and technology.
Estrella Immunopharma's R&D Expenses for the twelve months ending Jun 30, 2024 was $4.11M. For fiscal 2024 it was $4.11M.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2024 | Jun 30, 2024 | $4.11M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q1 FY2026CQ3 2025 | Jun 30, 2026 | $2.80M | +479.3% |
| Q4 FY2024CQ2 2024 | Jun 30, 2024 | $3.53M | – |
| Q3 FY2024CQ1 2024 | Mar 31, 2024 | $25.00K | – |
| Q2 FY2024CQ4 2023 | Dec 31, 2023 | $75.46K | – |
| Q1 FY2024CQ3 2023 | Sep 30, 2023 | $483.47K | – |
See a number that looks wrong?